<unk> , sold under the brand name Rukobia, is an antiretroviral medication for adults living with HIV/AIDS who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations. The most common adverse reaction is nausea. Severe adverse reactions included elevations in liver enzymes among participants also infected with hepatitis B or C virus, and changes in the immune system (immune reconstitution syndrome).<unk>  is an HIV entry inhibitor and a prodrug of temsavir (BMS-626529).<unk>  is a human immunodeficiency virus type 1 (HIV-1) gp120-directed attachment inhibitor. It was approved for medical use in the United States in July 2020, and in the European Union in February 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Fostemsavir
Saquinavir
Fosamprenavir
Coronavir
Abacavir
Entecavir
Tipranavir
Maribavir